CNCT19 for B-ALL with minimal remaining cancer after first remission
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 70 years old.
- You have B-ALL and are in first remission, but have a very small number of cancer cells still in your bone marrow (MRD-positive).
- Your cancer cells test positive for a marker called CD19.
- Your overall health is good enough for daily activities (ECOG score 0-1).
- Your organs (liver, kidneys, heart, lungs) are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell therapy called Inaticabtagene Autoleucel (CNCT19) for people with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) who are in their first complete remission. It aims to see if this treatment can help prevent relapse without a stem cell transplant.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
This trial tests a CAR-T cell therapy for adults who have just been diagnosed with a type of leukemia called Ph+ B-cell ALL. The treatment uses specially engineered immune cells to target and destroy cancer cells that have a specific marker (CD19 and CD22) and the Philadelphia chromosome. It may be an option for those who have not yet started standard chemotherapy.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets CD19 on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has not responded to treatment or has come back.
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.